Biomea Fusion Announced Saturday Near Doubling The Percentage Of Patients With Durable HbA1c Reduction In the 200 Mg Dose Cohorts
Biomea Fusion Announced Saturday Near Doubling The Percentage Of Patients With Durable HbA1c Reduction In the 200 Mg Dose Cohorts
Biomea Fusion週六宣佈，在200毫克劑量隊列中，持續減少Hba1c的患者比例幾乎翻了一番
Biomea Fusion, Inc. ("Biomea") (NASDAQ:BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseasesannounced top line data of the 200 mg dose cohorts from the ongoing Phase II clinical study (COVALENT-111) which will be presented in more detail at the International Conference on Advanced Technologies and Treatments of Diabetes (ATTD) in March 2024.
Biomea Fusion, Inc.（“Biomea”）（納斯達克股票代碼：BMEA）是一家臨床階段的生物製藥公司，致力於發現和開發用於治療和改善基因定義癌症和代謝性疾病患者生活的新型共價小分子。公佈了正在進行的二期臨床研究（COVALENT-111）中200 mg劑量隊列的頭號數據，該數據將在國際會議上詳細介紹 2024年3月的糖尿病先進技術和治療（ATTD）。
- At Week 26, 22 weeks after the last dose of BMF-219, the 200 mg cohorts increased the percentage of patients to approximately 40% with durable HbA1c reduction of 1% or more as compared to the 100 mg cohorts which reported earlier as 20%.
- To date, the dose escalation portion has shown after only 4 weeks of dosing with BMF-219 that patients across all dosing cohorts have consistently experienced generally meaningful HbA1c reductions and no serious adverse events or study discontinuations.
- 在第 26 周，即最後一劑 BMF-219 劑量 22 周後，200 毫克隊列將患者的百分比提高到大約 40%，HbA1c 持續降低 1% 或以上，而之前報告的 100 毫克隊列爲 20%。
- 迄今爲止，劑量遞增部分顯示，在給藥 BMF-219 僅四周後，所有給藥隊列的患者都經歷了總體上有意義的 HbA1c 降低，沒有嚴重的不良事件或研究中止。